223 related articles for article (PubMed ID: 35262781)
21. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.
Humbel M; Bellanger F; Fluder N; Horisberger A; Suffiotti M; Fenwick C; Ribi C; Comte D
Front Immunol; 2021; 12():645478. PubMed ID: 33828555
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
23. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
24. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7
Gogishvili T; Danhof S; Prommersberger S; Rydzek J; Schreder M; Brede C; Einsele H; Hudecek M
Blood; 2017 Dec; 130(26):2838-2847. PubMed ID: 29089311
[TBL] [Abstract][Full Text] [Related]
25. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
Friend R; Bhutani M; Voorhees PM; Usmani SZ
Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
[TBL] [Abstract][Full Text] [Related]
26. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
Taniwaki M; Yoshida M; Matsumoto Y; Shimura K; Kuroda J; Kaneko H
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018014. PubMed ID: 29531651
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi M; Soeda S; Sasaki M; Handa H; Imai Y; Tanaka N; Tanosaki S; Ito S; Odajima T; Sugimori H; Asayama T; Sunakawa M; Kaito Y; Kinoshita R; Kuribayashi Y; Onodera A; Moriya K; Tanaka J; Tsukune Y; Komatsu N; Inokuchi K; Tamura H
Oncotarget; 2018 Oct; 9(78):34784-34793. PubMed ID: 30410677
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic antibodies for multiple myeloma.
Ishida T
Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
[TBL] [Abstract][Full Text] [Related]
29. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Fantini M; David JM; Wong HC; Annunziata CM; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2019 Apr; 34(3):147-159. PubMed ID: 30601063
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
31. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Her JH; Pretscher D; Patra-Kneuer M; Schanzer J; Cho SY; Hwang YK; Hoeres T; Boxhammer R; Heitmueller C; Wilhelm M; Steidl S; Endell J
Cancer Immunol Immunother; 2022 Nov; 71(11):2829-2836. PubMed ID: 35348812
[TBL] [Abstract][Full Text] [Related]
32. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
Chu E; Wu J; Kang SS; Kang Y
Curr Oncol; 2023 Aug; 30(9):7891-7903. PubMed ID: 37754488
[TBL] [Abstract][Full Text] [Related]
33. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
34. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
36. Elotuzumab for the treatment of multiple myeloma.
Moreau P; Touzeau C
Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
Shrestha P; Astter Y; Davis DA; Zhou T; Yuan CM; Ramaswami R; Wang HW; Lurain K; Yarchoan R
Oncoimmunology; 2023; 12(1):2163784. PubMed ID: 36632565
[TBL] [Abstract][Full Text] [Related]
38. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
39. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.
Tomescu C; Tebas P; Montaner LJ
AIDS; 2017 Mar; 31(5):613-622. PubMed ID: 28225449
[TBL] [Abstract][Full Text] [Related]
40. Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.
Ernst D; Williams BA; Wang XH; Yoon N; Kim KP; Chiu J; Luo ZJ; Hermans KG; Krueger J; Keating A
Blood Cancer J; 2019 Jan; 9(2):6. PubMed ID: 30647406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
